2) Now we are covering @ASCO updates on #KRAS-mutated #cancers! Our author is #ASCO22 #FeaturedVoice Dr. Aakash Desai (@ADesaiMD) from @MayoHemOnc @MayoCancerCare and co-host @HemOncFellows. We will cover #KRAS in #LCSM, #GI malignancies & more. @Oncoalert @KRASKickers pic.twitter.com/d5I23Ul0NP
— @onc_ce (@onc_ce) June 29, 2022
4a) #KRAS was discovered in 1980s with implications in #cancer soon appreciated
— @onc_ce (@onc_ce) June 29, 2022
Alas, #KRAS remained “undruggable” until 2021 when 1st @FDAOncology approval occurred for KRASG12c #LCSM!
5) 2⃣ leading #KRASG12C ➖ #Sotorasib (Amgen) & #Adagrasib (Mirati), with others in development, we saw data on #adagrasib @ASCO #ASCO22 presented by @AlexSpiraMDPhD & @JSabari, #sotorasib trial in progress, Jacobio's JAB-21822 Phase I/II data & #combinations! @HemOncFellows pic.twitter.com/v9JfDwk11F
— @onc_ce (@onc_ce) June 29, 2022
7) #Sotorasib 960 mg qd received accelerated approval based on #CodeBreak100 @FSkoulidis @NEJM 🔓https://t.co/0qbOQTHrDs
— @onc_ce (@onc_ce) June 29, 2022
➡️ORR: 36%
➡️mDOR: 10 mths (1.3-11.1 mths)#Long-term data from @AACR #AACR22 by Dy et al
➡️ORR: 40.7%
➡️2 yr OS: 32.5%
🛑G3>=TRAEs: 20%
slides from #ASCO22 pic.twitter.com/Sb5XuAf1v8
8b) #CodeBreak201 testing 240 mg vs 960 mg 💊 in #KRASG12c mutated #LCSM in selected PDL1<1% STK11m
— @onc_ce (@onc_ce) June 29, 2022
🔚✴️ORR! @OncoAlert
Abstracts at 🔓https://t.co/BmBuoBotDj and 🔓https://t.co/BmBuoBotDj pic.twitter.com/NuwMgxLOEF
10) @ASCO #ASCO22 #Adagrasib @AlexSpiraMDPhD presented KRYSTAL-1, cohort A
— @onc_ce (@onc_ce) June 29, 2022
Janne et al. @NEJM https://t.co/i6g5FJ2xfS
➡️ORR: 42.9%
➡️mDOR: 8.5 mths (6.2-13.8 mths)@JSabari presented data on 🧠
➡️intracranial ORR: 33.3%
🛑G3>= TRAEs: 44%, 2 grade 5‼️ @KRASKickers #LCSM pic.twitter.com/WifyVTqoC1
12) KRASG12C inhibitor #3 JAB-21822 Phase 1 study was presented Abs#3809 (🔓https://t.co/q4P7S82qqj)
— @onc_ce (@onc_ce) June 29, 2022
➡️ORR all solid tumors: 40.8%
➡️ ORR #LCSM: 56.3% pic.twitter.com/B4pQbwxqvr
14) As we look forward, more 🎯💊 therapies with novel targets, combinations and KRASG12C ➖ are in pipeline and hopefully will improve #outcomes, great summaries of upcoming therapies by @kevansf@ShivaMalek https://t.co/Ztsw8k4syu
— @onc_ce (@onc_ce) June 29, 2022
👏 @Oncoalert @KRASKickers pic.twitter.com/EnIyQmoVJG
16) Go to https://t.co/G4ffFIAqu7 to claim your 🆓0.5h CE/#CME 🇺🇸🇨🇦🇪🇺🇬🇧. FOLLOW US here @onc_ce for more #accredited #tweetorials by expert authors!
— @onc_ce (@onc_ce) June 29, 2022